AI Summary
This article discusses how the EU has refused to grant marketing authorization for Leqembi, a drug for Alzheimer's, due to concerns about its risk of serious adverse events outweighing its ability to delay cognitive decline.
Leqembi’s EU-wide marketing authorization was refused because the drug’s effect on delaying cognitive decline does not counterbalance the risk for serious adverse events.
Medscape Medical News